Orforglipron
Also known as: LY3502970, OWL833
Oral non-peptide GLP-1 receptor agonist; small molecule mimicking GLP-1 activity with oral bioavailability. Note: not a peptide: small molecule GLP-1 agonist.
- Typical dose
- 800 mcg – 17.2 mg
- Frequency
- once daily
- Route
- Oral
- Half-life
- 2.29167 days
- Routes
- Oral
- Status
- FDA-approved (Foundayo, April 2025) for T2D and weight management
Benefits
- Oral administration (no injection)
- Weight loss
- Blood sugar control
- Daily pill convenience
Dosing
A common research range for Orforglipron is 800 mcg to 17.2 mg once daily. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Orforglipron has an approximate half-life of 2.29167 days. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
Room temperature.
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
Contraindications
- MEN2
- Medullary thyroid carcinoma
Track Orforglipron with Vial
Vial logs every Orforglipron dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Orforglipron is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.